论文部分内容阅读
目的鉴定OCI-Ly1、OCI-Ly8、OCI-Ly103株弥漫大B细胞(diffuselargeB-celllymphoma,DLBCL),并进行分子亚类分型及临床病理相关分析。方法采用细胞块切片HE染色观察细胞形态,运用CD3、CD20、CD10、Bcl-6、MUM-1抗体进行免疫标记确定其分子亚类;MTT法测定细胞的增殖活力。结果 OCI-Ly1和OCI-Ly8细胞形态以中心母细胞为主,OCI-Ly10以免疫母细胞为主。3株细胞CD20和CD10均弥漫阳性,CD3阴性。OCI-Ly1个别细胞Bcl-6阳性,MUM-1阴性;OCI-Ly8细胞Bcl-6、MUM-1均阴性;OCI-Ly10个别细胞Bcl-6阳性,MUM-1散在或簇状阳性,CD10和MUM-1的表达具有互补现象,在36例DLBCL临床病理标本中发现有7例(19%)CD10和MUM-1表达互补。OCI-Ly10增殖能力显著高于OCI-Ly1、OCI-Ly8(P<0.001)。结论 OCI-Ly1和OCI-Ly8属于GCB型,OCI-Ly10属于NC型(non-classfied);OCI-Ly10细胞系及组织标本CD10和MUM-1的表达互补现象有待进一步研究。
Objective To identify diffuse large B-cell lymphocytes (OCBCL) of OCI-Ly1, OCI-Ly8 and OCI-Ly103 cells and analyze the molecular subtypes and clinical pathology. Methods Cell morphology was observed by HE staining. The molecular subtypes were identified by immunofluorescent staining with CD3, CD20, CD10, Bcl-6 and MUM-1 antibodies. Cell viability was measured by MTT assay. Results OCI-Ly1 and OCI-Ly8 cells were mainly centroblasts and OCI-Ly10 cells were mainly immunoblasts. Three strains of CD20 and CD10 were diffuse positive, CD3 negative. Bcl-6 and MUM-1 were negative in OCI-Ly8 cells; Bcl-6 was positive in OCI-Ly10 cells, MUM-1 was scattered or clustered in positive and CD10 and MUM- The expression of MUM-1 was complementary. In 36 DLBCL clinical pathology specimens, 7 (19%) CD10 and MUM-1 genes were found to be complementary. The proliferation of OCI-Ly10 was significantly higher than that of OCI-Ly1 and OCI-Ly8 (P <0.001). Conclusion OCI-Ly1 and OCI-Ly8 belong to GCB type, OCI-Ly10 belong to NC type (non-classfied). The expression of CD10 and MUM-1 in OCI-Ly10 cell line and tissue specimens needs to be further studied.